article

1. The opioid industry's use of scientific evidence to advance claims about prescription opioid safety and effectiveness..  Health affairs scholar.  2:-. 2024
2. Biopharmaceutical pipeline funded by venture capital firms, 2014 to 2024..  Health affairs scholar.  2:-. 2024
3. Direct-to-Consumer Pharmacies: Disruptive Innovation or More Complexity?.  Journal of general internal medicine.  39:2131-2132. 2024
4. Tackling the excesses of pharmaceutical marketing and promotion..  BMJ (Clinical research ed.).  -. 2024
5. Comparison of prior authorization across insurers: cross sectional evidence from Medicare Advantage..  BMJ (Clinical research ed.).  -. 2024
6. Randomized Experiments to Reduce Overuse of Health Care: A Scoping Review..  Medical care.  62:263-269. 2024
7. Innovation in Development of Dermatologic Drugs Approved by the US Food and Drug Administration Between 2012 and 2022..  JAMA dermatology.  160:226-229. 2024
8. Medicaid Expansion And Outpatient Cardiovascular Care Use Among Low-Income Nonelderly Adults, 2012-15..  Health affairs (Project Hope).  42:1586-1594. 2023
9. Digital Privacy and Data Protection: From Ethical Principles to Action..  The American journal of bioethics : AJOB.  23:24-26. 2023
10. Association of High-Deductible Health Plans With Health Care Use and Costs for Patients With Cardiovascular Disease..  Journal of the American Heart Association.  12:-. 2023
11. Payer-Negotiated Prices for Cardiac Electrophysiology Procedures at 2022-2023 Top 100 US News & World Report for Cardiology and Heart Surgery Hospitals..  Circulation. Arrhythmia and electrophysiology.  16:-. 2023
12. Medical journals and advertiser tracking-Consequences for patients, clinicians, and editors..  Digital health.  -. 2023
13. Consumer Views on Privacy Protections and Sharing of Personal Digital Health Information..  JAMA network open.  6:-. 2023
14. Consumer Confidence in Public and Private Organizations to Use Their Digital Health Data Responsibly..  Journal of general internal medicine.  38:1087-1090. 2022
15. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017..  JAMA health forum.  3:-. 2022
16. Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021..  JAMA health forum.  3:-. 2022
17. Prevalence of Third-party Tracking on Medical Journal Websites..  JAMA health forum.  3:-. 2022
18. An Unnecessary Gift for COVID-19 Vaccines and Therapeutics: The Medical Countermeasure Priority Review Voucher..  American journal of public health.  111:1923-1926. 2021
19. Assessing community health research capacity across stakeholders: adapting a tool..  Health promotion international.  36:1198-1208. 2021
20. Naloxone prescriptions following emergency department encounters for opioid use disorder, overdose, or withdrawal..  The American journal of emergency medicine.  154-157. 2021
21. Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics..  Journal of general internal medicine.  35:1928-1930. 2019
22. Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration..  JAMA network open.  2:-. 2019
23. Generic Drugs in the United States: Policies to Address Pricing and Competition..  Clinical pharmacology and therapeutics.  105:329-337. 2019
24. The Impact of Off-Patent Drug Acquisitions on Prices..  Journal of general internal medicine.  33:1007-1009. 2018
25. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study..  BMJ (Clinical research ed.).  -. 2018
26. High Costs of FDA Approval for Formerly Unapproved Marketed Drugs..  JAMA.  318:2181-2182. 2017
27. The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States..  Journal of managed care & specialty pharmacy.  23:1066-1076. 2017
28. Prioritization of Generic Drug Review-Reply..  JAMA internal medicine.  177:141-142. 2017
29. The Rising Price of Naloxone - Risks to Efforts to Stem Overdose Deaths..  The New England journal of medicine.  375:2213-2215. 2016
30. Generic Drug Approvals Since the 1984 Hatch-Waxman Act..  JAMA internal medicine.  176:1391-3. 2016